A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Recruiting

Phase 1

JNJ-88549968A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Sponsor:

Janssen Research & Development, LLC

Code:

NCT06150157

Conditions

Myeloproliferative Disorders

Essential Thrombocythemia

Neoplasms

Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

JNJ-88549968

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-04. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-07-20.